These 2 ASX 200 shares stand out for investors willing to think in years rather than days: CSL Ltd (ASX: CSL) and Temple & Webster Group Ltd (ASX: TPW).
One sells essential medicines to the world. The other sells couches, lamps and coffee tables to Australians who like shopping from the sofa.
Different businesses, different risks, but both have credible paths to long-term wealth creation.
CSL Ltd (ASX: CSL)
CSL sits at the heavyweight end of the market. The $85 billion ASX 200 share operates a global biotechnology empire built around plasma-derived therapies, vaccines and specialty medicines. Demand for these products doesn't disappear when economies slow or consumers tighten their belts. People still need treatment, and hospitals still place orders.
The ASX 200 biotech stock has stumbled over the past couple of years as margins came under pressure and earnings upgrades failed to materialise. That has tested investor patience.
But CSL continues to generate strong cash flow, invest heavily in research and streamline its operations. Its scale, pricing power and global reach give it an edge few competitors can match. Over a 10-year stretch, that combination matters far more than a rough patch or two along the way.
Closing the week at $175.53, the company's shares remain close to their 52-week low. The ASX 200 share tumbled more than 30% in the past 6 months.
For a business long regarded as one of the ASX's highest-quality names, such a sharp pullback inevitably prompts the question: does this represent a rare long-term buying opportunity?
Most analysts do think this might the time to pounce and rate CSL a buy or even a strong buy. They set the average 12-month price target at $232, a potential gain of 32%.
Temple & Webster Ltd (ASX: TPW)
Temple & Webster tells a very different story. The ASX 200 share operates an online-only homewares platform that offers thousands of products without the burden of running a network of physical stores. The model keeps costs low and allows the business to scale as demand grows.
Like most growth stocks, Temple & Webster has ridden a volatile path. Rising interest rates, housing slowdowns and cautious consumers have weighed on sentiment. Yet the business continues to win customers, improve logistics and expand its product range. As conditions normalise and online retail continues to take share from traditional stores, Temple & Webster has room to grow into a much larger business than it is today.
Just like CSL, Temple & Webster has been hovering around 52-week lows. In the past 6 months the ASX 200 share has lost 40% of its value and the broker community has taken notice.
Most analysts rate the stock now as a buy or strong buy, with an average 12-month price target of $20.42, implying around 60% upside. The most bullish forecasts point to potential gains of more than 115%.
